Hello, in March 2017 I lost my mother to senile dementia.  Her rapid demise took her to her grave in little more than 12 months, my family and I were devastated at the speed of this illness and the upsetting nature that accompanies it.  As a result of a by chance mention of the Prime Golf day in 2019 (pre Covid), I was asked to help by auctioneering kindly donated items to a room of avid golfers post a hard days work on the course.  The consumption of generosity in that room inspired me to not only repeat my very novice auctioneering skills, but to help Prime to raise the 250k working along side the Alzheimer’s Society.  

Due to the pandemic, the Golf day didn’t resume until 2022, and in that period, I felt more driven to ensure that the 2022 auction was an even bigger success and on that day there was a massive £26,000 raised.  I am very lucky to be employed in a business that covers a very unique area of the financial world.  Within my circle of friends and business partners, we have been lucky enough to have been donated auction items that, one could safely say, wouldn’t be out of place in any of the top 5 golf clubs in the UK.  That generosity continues and has been extended into the 2023 event.

Its my duty to say a big thank you to all of our generous donators (and bidders), it makes my role so much easier on the day – lets face it, Braiswick in Colchester isn’t the largest club on the planet, but within those competing on the day there are beating hearts that are strong enough to continue to commit to that ever decreasing target of 250k.

Finally, I wanted to thank Robyn and Peter, not only for the incredible work that they do for this charity for Margaret and many many others who will benefit from the target raise, but for inviting me back again as part of the team.

I wanted to go back to the point I made about the financial world that I work in, great strides have been and are being made to find a cure.  In March this year EQT Life Sciences (a Swedish Private Equity house) closed a Eu260m fund dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies across the spectrum of Neurodegenerative diseases, and investors include the Alzeimer’s Association, The European Investment Fund, several global pharmaceutical and insurance companies – the funds initial target raise was Eu100m. Through this work and the work of the Alzheimer’s Society there is light at the end of the tunnel in the battle against Alzheimer’s and other dementia related diseases.

Thanks for your support.